Leerink Partners Maintains Roivant Sciences(ROIV.US) With Buy Rating
Goldman Sachs Maintains Roivant Sciences(ROIV.US) With Buy Rating
Strong Buy Rating for Roivant Sciences Backed by Strategic Dermavant Divestiture and Promising Clinical Pipeline
H.C. Wainwright Maintains Roivant Sciences(ROIV.US) With Buy Rating, Maintains Target Price $18
Analysts Offer Insights on Healthcare Companies: Progyny (PGNY) and Roivant Sciences (ROIV)
Roivant Sciences Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $18 Price Target
TD Cowen Maintains Roivant Sciences(ROIV.US) With Buy Rating
Jefferies Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $18
BofA Securities Maintains Roivant Sciences(ROIV.US) With Hold Rating, Maintains Target Price $12.5
TD Cowen Maintains Roivant Sciences(ROIV.US) With Buy Rating
B of A Securities Maintains Neutral on Roivant Sciences, Raises Price Target to $12.5
A Quick Look at Today's Ratings for Roivant Sciences(ROIV.US), With a Forecast Between $12.5 to $18
Roivant Sciences Analyst Ratings
Buy Rating Affirmed on Roivant Sciences: Promising Drug Pipeline and Strategic Acquisitions
Goldman Sachs Reaffirms Their Buy Rating on Roivant Sciences (ROIV)
Roivant Sciences Analyst Ratings
Roivant Sciences (ROIV) Receives a Buy From H.C. Wainwright
H.C. Wainwright Maintains Roivant Sciences(ROIV.US) With Buy Rating, Maintains Target Price $18
Leerink Partners Maintains Roivant Sciences(ROIV.US) With Buy Rating, Announces Target Price $17